SENSEX NIFTY
Apr 11, 2012, 10.34 PM IST | Source: PTI

Piramal gets European regulatory nod to sell BST-CarGel

Piramal Healthcare Ltd today announced that it has received European regulatory approval to sell BST-CarGel, a bio-orthopaedic product. The European regulatory approval will enable Piramal Helthcare to commercialize BST-CarGel in all of the countries in the European Union.

Piramal gets European regulatory nod to sell BST-CarGel

Piramal Healthcare Ltd today announced that it has received European regulatory approval to sell BST-CarGel, a bio-orthopaedic product. The European regulatory approval will enable Piramal Helthcare to commercialize BST-CarGel in all of the countries in the European Union.

This approval will also serve as the basis to obtain commercial authorization for the product in other geographic areas of the world such as the Middle East, the Asia Pacific region, South America and other countries including India. Piramal Healthcare plans to launch BST-CarGel for commercial sale in the fourth quarter of the 2012 calendar year after completing user studies with key opinion leaders.

"Following approval of Piramal's first innovative product for regenerative medicine, we are looking forward to launch BST-CarGel to treat patients with cartilage injuries of the knee around the world," Piramal Healthcare director Swati Piramal told reporters here. Commenting on the development, Ajay Piramal, Chairman, Piramal Group said, "BST-Cargel provides us with a superior way to address significant unmet medical needs in the global knee cartilage repair market.

The current European approval provides access to a USD 200 million market in Europe with the potential for a larger market with greater penetration of treatment in Europe." BST-CarGel, a EU class III medical device, is a novel natural polysaccharide based liquid scaffold which, combined with the patient's whole blood, is then implanted into a debrided cartilage lesion prepared with bone marrow access.

As demonstrated in a controlled clinical trial, this procedure results in a superior cartilage repair volume and quality compared to the standard of care treatment with the goal of offering a more durable longer term treatment. Piramal Healthcare originally invested into the BST-CarGel technology in 2006 and subsequently in 2010, acquired the assets relating to BST-CarGel from BioSyntech Technologies Inc, a company located in Montreal, Canada.

Piramal Enter stock price

On November 24, 2014, Piramal Enterprises closed at Rs 844.60, up Rs 0.00, or 0.00 percent. The 52-week high of the share was Rs 862.05 and the 52-week low was Rs 482.65.


The company's trailing 12-month (TTM) EPS was at Rs 130.67 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 6.46. The latest book value of the company is Rs 528.91 per share. At current value, the price-to-book value of the company is 1.60.

Set email alert for

ADS BY GOOGLE

video of the day

India stays amid the best games in town: BNP's Raychaudhuri

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.